Fairness of financial penalties to improve control of Clostridium difficile

BMJ

Volumn 337, Issue , 2008, Pages

  Walker, a Sarah ^a,b   Spiegelhalter, David ^c,d   Crook, Derrick W ^a   Wyllie, David ^e   Morris, James ^a   Peto, Tim E A ^a  

^a NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GREAT BRITAIN; HEALTH POLICY; HUMANS; PRIMARY HEALTH CARE; REIMBURSEMENT, INCENTIVE; STATE MEDICINE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION RISK; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PUNISHMENT; REVIEW; RISK REDUCTION;

EID: 57749200924     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.a2097     Document Type: Article

References (16)

1. Duckett SJ. Design of price incentives for adjunct policy goals in formula funding for hospitals and health services. BMC Health Serv Res 2008; 8: 72.
2. Lindenauer PK, Remus D, Roman S, Rothberg MB, Benjamin EM, Ma A, et al. Public reporting and pay for performance in hospital quality improvement. N Engl J Med 2007; 356: 486–496.
3. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S. Does pay-for-performance improve the quality of health care? Ann Intern Med 2006; 145: 265–272.
4. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433–2441.
5. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173: 1037–1042.
6. UK Department of Health. National target to reduce Clostridium difficile infections: SHA envelopes–reissue. www.dh.gov.uk (search for: 9397).
7. Health Protection Agency. Clostridium difficile. www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1216193832974.
8. Fowler S, Webber A, Cooper BS, Phimister A, Price K, Carter Y, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007; 59: 990–995.
9. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46(suppl 1):S43–9.
10. Muto CA, Blank MK, Marsh JW, Vergis EN, O'Leary MM, Shutt KA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007; 45: 1266–1273.
11. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(suppl 2):S112–21.
12. Healy MJ, Goldstein H. Regression to the mean. Ann Hum Biol 1978; 5: 277–280.
13. Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ 2003; 326: 1083–1084.
14. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2005; 11: 59–65.
15. Healthcare Commission. Statistical banding for national target indicators, annual health check 2006/2007. http://ratings2007.healthcarecommission.org.uk/Indicators_2007/Downloads/Stats_banding_targets_methods_2_12–0.pdf.
16. Cite this as: BMJ 2008;337:a2097